BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.640
-0.010 (-0.38%)
Mar 9, 2026, 4:00 PM EDT - Market closed
BioLineRx Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 12 | 23 | 115 | 28 | 99 | 60 | |
| Market Cap Growth | -9.94% | -79.62% | 304.79% | -71.33% | 65.98% | 124.34% | |
| Enterprise Value | -3 | 24 | 102 | -19 | 40 | 47 | |
| Last Close Price | 2.65 | 8.56 | 62.80 | 23.60 | 81.60 | 100.80 | |
| PS Ratio | 0.93 | 0.81 | 24.01 | - | - | - | |
| PB Ratio | 0.60 | 1.75 | 8.72 | 0.56 | 1.46 | 2.72 | |
| P/TBV Ratio | 1.29 | 7.80 | - | 0.98 | 2.14 | 189.39 | |
| EV/Sales Ratio | - | 0.83 | 21.22 | - | - | - | |
| Debt / Equity Ratio | 0.58 | 1.12 | 0.88 | 0.24 | 0.07 | 0.35 | |
| Net Debt / Equity Ratio | -0.71 | -0.34 | -2.37 | -0.76 | -0.77 | -0.68 | |
| Net Debt / EBITDA Ratio | 1.65 | 0.29 | 0.75 | 1.36 | 2.18 | 0.68 | |
| Net Debt / FCF Ratio | 1.03 | 0.10 | 1.38 | 1.47 | 2.22 | 0.64 | |
| Asset Turnover | 0.28 | 0.56 | 0.07 | - | - | - | |
| Inventory Turnover | 2.19 | 3.63 | - | - | - | - | |
| Quick Ratio | 1.90 | 1.52 | 1.02 | 4.85 | 5.89 | 2.14 | |
| Current Ratio | 2.09 | 1.76 | 1.10 | 4.87 | 5.91 | 2.15 | |
| Return on Equity (ROE) | -21.23% | -69.11% | -189.23% | -41.96% | -60.04% | -108.36% | |
| Return on Assets (ROA) | -13.60% | -23.28% | -38.30% | -23.10% | -24.07% | -28.42% | |
| Return on Capital Employed (ROCE) | -38.50% | -81.50% | -203.40% | -44.40% | -34.60% | -62.60% | |
| Earnings Yield | -25.27% | -39.26% | -52.59% | -87.63% | -27.24% | -50.16% | |
| FCF Yield | -114.40% | -187.02% | -19.72% | -92.62% | -23.83% | -38.78% | |
| Buyback Yield / Dilution | -86.44% | -24.37% | -24.47% | -16.75% | -162.19% | -72.70% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.